VEGFA and lymphangioma: Preclinical data suggest that vascular endothelial growth factor (VEGF) inhibition promotes cytotoxic T-cell infiltration to help overcome the immune tolerant environment of the liver.39 The efficacy of combining a VEGF inhibitor with immune checkpoint blockade was reported in a subgroup analysis of IMpower150, which showed improved outcomes in patients with LM receiving combination therapy (atezolizumab/bevacizumab/carboplatin/paclitaxel vs bevacizumab/carboplatin/paclitaxel, HR 0.68, median OS 13.2 months vs 9.1 months).40